FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marco Gambacciani

Research Profile

Procedures

Disorders

Concepts & Ideas

Physiology

Postmenopause

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Marco Gambacciani
Progesterone to treat vasomotor symptoms.
Santiago Palacios; Fatima Romao; Serge Rozenberg; Rafael Sánchez Borrego; John C Stevenson; Claus Christiansen; Marco Gambacciani; Payman Hadji; Morten Karsdal; Irene V Lambrinoudaki; Stefano Lello; Barbara O'Beirne; Zion Ben Rafael
Recommendations on the management of fragility fracture risk in women younger than 70 years.
Santiago Palacios; Margaret Rees; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Mark Brincat; Cemal Tamer Erel; Marco Gambacciani; Irene V Lambrinoudaki; Mette H Moen; Serge Rozenberg
EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marco Gambacciani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Marco Gambacciani
Progesterone to treat vasomotor symptoms.
Climacteric : the journal of the International Menopause Society 2012;15(5):501-2.
2012: Santiago Palacios; Fatima Romao; Serge Rozenberg; Rafael Sánchez Borrego; John C Stevenson; Claus Christiansen; Marco Gambacciani; Payman Hadji; Morten Karsdal; Irene V Lambrinoudaki; Stefano Lello; Barbara O'Beirne; Zion Ben Rafael
Recommendations on the management of fragility fracture risk in women younger than 70 years.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2012;28(10):770-86.
2012: Santiago Palacios; Margaret Rees; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Mark Brincat; Cemal Tamer Erel; Marco Gambacciani; Irene V Lambrinoudaki; Mette H Moen; Serge Rozenberg
EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
Maturitas 2012;71(2):194-8.
2011: Andrea R Genazzani; Marco Gambacciani
Vasomotor symptoms and negative affect: time to act.
Menopause (New York, N.Y.) 2011;18(12):1265-6.
2011: Florence Tremollieres; Marc Brincat; C Tamer Erel; Marco Gambacciani; Irene Lambrinoudaki; Mette H Moen; Karin Schenck-Gustafsson; Svetlana Vujovic; Serge Rozenberg; Margaret Rees
EMAS position statement: Managing menopausal women with a personal or family history of VTE.
Maturitas 2011;69(2):195-8.
2011: Karin Schenck-Gustafsson; Mark Brincat; C Tamer Erel; Marco Gambacciani; Irene V Lambrinoudaki; Mette H Moen; Florence Tremollieres; Svetlana Vujovic; Serge Rozenberg; Margaret Rees
EMAS position statement: Managing the menopause in the context of coronary heart disease.
Maturitas 2011;68(1):94-7.
2011: Mark Brincat; Jean Calleja-Agius; C Tamer Erel; Marco Gambacciani; Irene V Lambrinoudaki; Mette H Moen; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Margaret Rees; Serge Rozenberg
EMAS position statement: Bone densitometry screening for osteoporosis.
Maturitas 2011;68(1):98-101.
2010: Franca Fruzzetti; Daria Perini; Veronica Lazzarini; Donatella Parrini; Marco Gambacciani; Andrea Riccardo Genazzani
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fertility and sterility 2010;94(5):1793-8.
2010: Mette H Moen; Margaret Rees; Marc Brincat; Tamer Erel; Marco Gambacciani; Irene Lambrinoudaki; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Serge Rozenberg
EMAS position statement: Managing the menopause in women with a past history of endometriosis.
Maturitas 2010;67(1):94-7.
2010: Svetlana Vujovic; Marc Brincat; Tamer Erel; Marco Gambacciani; Irene Lambrinoudaki; Mette H Moen; Karin Schenck-Gustafsson; Florence Tremollieres; Serge Rozenberg; Margaret Rees
EMAS position statement: Managing women with premature ovarian failure.
Maturitas 2010;67(1):91-3.
2010: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; GRaham Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Postmenopausal hormone therapy: an Endocrine Society scientific statement.
The Journal of clinical endocrinology and metabolism 2010;95(7 Suppl 1):s1-s66.
2010: Irene V Lambrinoudaki; Marc Brincat; Cemal Tamer Erel; Marco Gambacciani; Mette H Moen; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Margaret Rees; Serge Rozenberg
EMAS position statement: managing obese postmenopausal women.
Maturitas 2010;66(3):323-6.
2010: Cemal Tamer Erel; Marc Brincat; Marco Gambacciani; Irene V Lambrinoudaki; Mette H Moen; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Serge Rozenberg; Margaret Rees
EMAS position statement: managing the menopause in women with epilepsy.
Maturitas 2010;66(3):327-8.
2009: Marco Gambacciani; A Pepe
Vasomotor symptoms and cardiovascular risk.
Climacteric : the journal of the International Menopause Society 2009;12 Suppl 1():32-5.
2009: Giuseppe M C Rosano; Silvia Maffei; Maria G Andreassi; Cristiana Vitale; Cristina Vassalle; Marco Gambacciani; Marco Stramba-Badiale; Giuseppe Mercuro
Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
Journal of cardiovascular medicine (Hagerstown, Md.) 2009;10(1):85-92.
2008: Umberto Omodei; Caterina Benussi; Francesca Ramazzotto; Michela Feller; Marco Gambacciani
Risk identification of osteoporosis in postmenopausal women by a simple algorithm based on ultrasound densitometry and body mass index.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2008;11(3):412-6.
2008: Marco Gambacciani; Barbara Cappagli; Massimo Ciaponi; Antonia Pepe; Francesca Vacca; Andrea R Genazzani
Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Maturitas 2008;59(1):2-6.
2007: P Collins; Giuseppe Rosano; C Casey; C Daly; Marco Gambacciani; Peyman Hadji; R Kaaja; T Mikkola; S Palacios; Richard A Preston; T Simon; J Stevenson; Marco Stramba-Badiale
Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists.
Climacteric : the journal of the International Menopause Society 2007;10(6):508-26.
2007: Peter Collins; Giuseppe Rosano; Catherine Casey; Caroline Daly; Marco Gambacciani; Peyman Hadji; Risto Kaaja; Tomi Mikkola; Santiago Palacios; Richard A Preston; Tabassome Simon; John Stevenson; Marco Stramba-Badiale
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists].
Kardiologia polska 2007;65(11):1331-46; discussion 1347-49.
2007: Franca Fruzzetti; Veronica Lazzarini; Cabiria Ricci; Barbara Quirici; Marco Gambacciani; Anna Maria Paoletti; Andrea R Genazzani
Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
Contraception 2007;76(3):190-4.
2007: Marco Gambacciani; A Pepe; Barbara Cappagli; E Palmieri; Andrea R Genazzani
The relative contributions of menopause and aging to postmenopausal reduction in intervertebral disk height.
Climacteric : the journal of the International Menopause Society 2007;10(4):298-305.
2007: Marco Gambacciani; Massimo Ciaponi; Andrea R Genazzani
The HRT misuse and osteoporosis epidemic: a possible future scenario.
Climacteric : the journal of the International Menopause Society 2007;10(4):273-5.
2007: Peter Collins; Giuseppe Rosano; Catherine Casey; Caroline Daly; Marco Gambacciani; Peyman Hadji; Risto Kaaja; Tomi Mikkola; Santiago Palacios; Richard A Preston; Tabassome Simon; John Stevenson; Marco Stramba-Badiale
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists.
European heart journal 2007;28(16):2028-40.
2007: Marco Gambacciani
The return of hormonal therapy.
Women's health (London, England) 2007;3(4):421-2.
2007: Marco Gambacciani; A Pepe
Menopause and related problems.
Minerva medica 2007;98(3):191-201.
2007: Amos Pines; David W Sturdee; Martin H Birkhäuser; H P G Schneider; Marco Gambacciani; Nick Panay
IMS updated recommendations on postmenopausal hormone therapy.
Climacteric : the journal of the International Menopause Society 2007;10(3):181-94.
2007: Andrea R Genazzani; Marco Gambacciani; Tommaso Simoncini
The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2007;23(4):183-5.
2007: Andrea R Genazzani; Marco Gambacciani; Tommaso Simoncini
Menopause and aging, quality of life and sexuality.
Climacteric : the journal of the International Menopause Society 2007;10(2):88-96.
2007: Marco Gambacciani; Paolo Mannella
Homocysteine, menopause and cardiovascular disease.
Menopause international 2007;13(1):23-6.
2007: Andrea Genazzani; Marco Gambacciani; Tommaso Simoncini; R Anniverno; A M Becorpi; N Biglia; M L Brandi; S Guaschino; Stefano Lello; M Massobrio; Gian Benedetto Melis; C Mencacci; M G Modena; Carmine Nappi; R E Nappi; S Pecorelli; Felice Petraglia; Giuseppe Rosano; Giovan Battista Serra; Piero Sismondi; S Taddei; F Tonelli
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2007;23(8):436-44.
2006: Marco Gambacciani; Barbara Cappagli; Veronica Lazzarini; Massimo Ciaponi; Franca Fruzzetti; Andrea R Genazzani
Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density.
Maturitas 2006;54(2):176-80.
2006: Andrea R Genazzani; Marco Gambacciani
Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2006;22(3):145-50.
2006: Marco Gambacciani; Andrea R Genazzani
From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2006;22(3):115-6.
2005: Marco Gambacciani; D Spielmann; Andrea R Genazzani
Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2005;21(2):65-73.
2005: Andrea R Genazzani; Marco Gambacciani; H P G Schneider; C Christiansen
Postmenopausal osteoporosis: therapeutic options.
Climacteric : the journal of the International Menopause Society 2005;8(2):99-109.
2005: Antonello Silvestri; Marco Gambacciani; Cristiana Vitale; Palmiero Monteleone; Massimo Ciaponi; Massimo Fini; Andrea R Genazzani; Giuseppe Mercuro; Giuseppe Rosano
Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk.
Maturitas 2005;50(4):305-11.
2005: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Palmiero Monteleone; Caterina Benussi; Gemma Bevilacqua; Francesca Vacca; Andrea R Genazzani
Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women.
Maturitas 2005;50(2):91-7.
2004: Frederick Naftolin; H P G Schneider; David W Sturdee; Martin H Birkhäuser; M P Brincat; Marco Gambacciani; A R Genazzani; K K Limpaphayom; S O'Neill; S Palacios; Amos Pines; N Siseles; D Tan; H G Burger
Guidelines for hormone treatment of women in the menopausal transition and beyond.
Climacteric : the journal of the International Menopause Society 2004;7(4):333-7.
2004: Marco Gambacciani; F Vacca
Postmenopausal osteoporosis and hormone replacement therapy.
Minerva medica 2004;95(6):507-20.
2004: Marco Gambacciani; Palmiero Monteleone; Massimo Ciaponi; A Sacco; Andrea R Genazzani
Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women.
Maturitas 2004;48(4):421-4.
2004: Marco Gambacciani
New HRT options for the treatment of menopausal symptoms and the maintenance of quality of life in postmenopausal women.
Endocrine 2004;24(3):231-8.
2004: Henry Burger; David Archer; David Barlow; Martin H Birkhäuser; Joaquim Calaf-Alsina; Marco Gambacciani; Andrea Genazzani; Peyman Hadji; Ole-Erik Iversen; Herbert Kuhl; Rogerio A Lobo; Thierry Maudelonde; Manuel Neves e Castro; Morris Notelovitz; Santiago Palacios; Tomasz Paszkowski; Eitan Peer; Amos Pines; Göran Samsioe; John Stevenson; Sven O Skouby; David W Sturdee; Tobie de Villiers; Malcolm Whitehead; Olavi Ylikorkala
Practical recommendations for hormone replacement therapy in the peri- and postmenopause.
Climacteric : the journal of the International Menopause Society 2004;7(2):210-6.
2004: Marco Gambacciani; Andrea R Genazzani
The Xmas present for women's health: a strike to osteoporosis prevention.
Maturitas 2004;48(1):9-11.
2004: Andrea R Genazzani; Marco Gambacciani; Tommaso Simoncini
Estrogens and women's health: a scary or a fairy tale?
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2004;18(4):175-8.
2004: Marco Gambacciani; Domenico De Aloysio; David Elia; Marius J van der Mooren; Peyman Hadji; Christian Wüster
Quantitative ultrasound (QUS) of bone in the management of postmenopausal women.
Maturitas 2004;47(2):139-49.
2004: Marco Gambacciani; Andrea R Genazzani
The osteoporosis dilemma.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2004;18(2):59-61.
2004: Marco Gambacciani; Palmiero Monteleone; Massimo Ciaponi; Alessandro Sacco; Andrea R Genazzani
Effects of oral contraceptives on bone mineral density.
Treatments in endocrinology 2004;3(3):191-6.
2004: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Palmiero Monteleone; Caterina Benussi; Gemma Bevilacqua; Andrea R Genazzani
A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2004;18(1):9-16.
2003: Andrea R Genazzani; Marco Gambacciani
The sound of an International anti-HRT herald.
Maturitas 2003;46(2):105-6.
2003: Andrea R Genazzani; Marco Gambacciani; Tommaso Simoncini; H P G Schneider
"Controversial issues in climacteric medicine" series 3rd Pisa workshop "HRT in climacteric and aging brain". Pisa, Italy, 15-18 March 2003.
Maturitas 2003;46(1):7-26.
2003: Andrea R Genazzani; Marco Gambacciani; Tommaso Simoncini; H P G Schneider
Hormone replacement therapy in climacteric and aging brain. International Menopause Society Expert Workshop, 15-18 March 2003, Pisa, Italy.
Climacteric : the journal of the International Menopause Society 2003;6(3):188-203.
2003: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Palmiero Monteleone; Caterina Benussi; Gemma Bevilacqua; Andrea R Genazzani
Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy.
Maturitas 2003;45(3):175-83.
2003: Marco Gambacciani; Andrea R Genazzani
Hormone therapy.
Menopause (New York, N.Y.) 2003;10(3):266-7; author reply 267.
2003: Andrea R Genazzani; Ilaria Lombardi; G Borgioli; I di Bono; Elena Casarosa; Marco Gambacciani; Marco Palumbo; Alessandro Genazzani; Michele Luisi
Adrenal function under long-term raloxifene administration.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2003;17(2):159-68.
2003: Marco Gambacciani; Palmiero Monteleone; A Sacco; Andrea R Genazzani
Hormone replacement therapy and endometrial, ovarian and colorectal cancer.
Best practice & research. Clinical endocrinology & metabolism 2003;17(1):139-47.
2003: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Palmiero Monteleone; Caterina Benussi; Gemma Bevilacqua; Andrea R Genazzani
Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women.
Maturitas 2003;44(2):157-63.
2002: Marco Gambacciani; Palmiero Monteleone; Cristiana Vitale; Antonello Silvestri; Massimo Fini; Andrea R Genazzani; Giuseppe Rosano
Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial.
Maturitas 2002;43(2):117-23.
2002: Andrea R Genazzani; Palmiero Monteleone; Marco Gambacciani
Hormonal influence on the central nervous system.
Maturitas 2002;43 Suppl 1():S11-7.
2002: Andrea R Genazzani; A Nicolucci; Carlo Campagnoli; P Crosignani; Carmine Nappi; Giovan Battista Serra; E Bottiglioni; A Cianci; Domenico De Aloysio; C Donati Sarti; Marco Gambacciani; Palmiero Monteleone; Alessandro Genazzani; S Guaschino; G Palumbo; Felice Petraglia; S Schonauer; A Volpe; T Di Paolantonio; M Nagni; A Tempesta; GA Coronel
Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users.
Maturitas 2002;42(4):267-80.
2002: Marco Gambacciani; Giuseppe Rosano; Patrizia Monteleone; Massimo Fini; Andrea R Genazzani
Clinical relevance of the HERS trial.
Lancet 2002;360(9333):641.
2002: Marco Gambacciani; Palmiero Monteleone; Andrea R Genazzani
Low-dose hormone replacement therapy: effects on bone.
Climacteric : the journal of the International Menopause Society 2002;5(2):135-9.
2002: Carlo Campagnoli; Paola Colombo; Domenico De Aloysio; Marco Gambacciani; Irene Grazioli; Carmine Nappi; Giovan Battista Serra; Andrea R Genazzani
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate.
Maturitas 2002;41(4):299-311.
2002: Andrea R Genazzani; A Nicolucci; Carlo Campagnoli; P Crosignani; Carmine Nappi; Giovan Battista Serra; E Bottiglioni; A Cianci; Domenico De Aloysio; C Donati Sarti; Marco Gambacciani; Palmiero Monteleone; Massimo Ciaponi; Alessandro Genazzani; S Guaschino; G Palumbo; Felice Petraglia; S Schonauer; A Volpe; GA Coronel; T Di Paolantonio; M Nagni; A Tempesta
Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers.
Climacteric : the journal of the International Menopause Society 2002;5(1):70-7.
2001: Marco Gambacciani; Andrea R Genazzani
Hormone replacement therapy: the benefits in tailoring the regimen and dose.
Maturitas 2001;40(3):195-201.
2001: Andrea R Genazzani; Angiolo Gadducci; Marco Gambacciani
Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer.
Maturitas 2001;40(2):117-30.
2001: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Andrea R Genazzani
Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
American journal of obstetrics and gynecology 2001;185(5):1180-5.
2001: Andrea R Genazzani; A Gadducci; Marco Gambacciani
Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Climacteric : the journal of the International Menopause Society 2001;4(3):181-93.
2001: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; L De Simone; R Orlandi; Andrea R Genazzani
Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy.
Maturitas 2001;39(2):125-32.
2001: Andrea R Genazzani; Marco Gambacciani
HRT in the third millennium.
Maturitas 2001;38 Suppl 1():S49-55.
2000: Francesco S Pansini; Alberto Bacchi-Modena; Domenico De Aloysio; Marco Gambacciani; Michele Meschia; F Parazzini; G Sciacchitano; R di Micco; Elena Peruzzi; G Maiocchi
Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy.
Climacteric : the journal of the International Menopause Society 2000;3(4):241-7.
2000: Andrea R Genazzani; Marco Gambacciani
Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13-16 October 2000, royal society of medicine, London, UK.
Climacteric : the journal of the International Menopause Society 2000;3(4):233-40.
2000: Marco Gambacciani; Massimo Ciaponi
Postmenopausal osteoporosis management.
Current opinion in obstetrics & gynecology 2000;12(3):189-97.
2000: Michele Meschia; Francesco S Pansini; Alberto Bacchi Modena; Domenico De Aloysio; Marco Gambacciani; F Parazzini; Carlo Campagnoli; G Maiocchi; Elena Peruzzi
Determinants of age at menopause in Italy: results from a large cross-sectional study. ICARUS Study Group. Italian Climacteric Research Group Study.
Maturitas 2000;34(2):119-25.
2000: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Caterina Benussi; Andrea R Genazzani
Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2000;11(6):544-8.
1999: Andrea R Genazzani; Marco Gambacciani
Hormone replacement therapy: the perspectives for the 21st century.
Maturitas 1999;32(1):11-7.
1999: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; Caterina Benussi; L De Simone; Andrea R Genazzani
Climacteric modifications in body weight and fat tissue distribution.
Climacteric : the journal of the International Menopause Society 1999;2(1):37-44.
1999: Marco Gambacciani; Barbara Cappagli; Massimo Ciaponi; Caterina Benussi; Andrea R Genazzani
Hormone replacement therapy in perimenopause: effect of a low dose oral contraceptive preparation on bone quantitative ultrasound characteristics.
Menopause (New York, N.Y.) 1999;6(1):43-8.
1998: Marco Gambacciani; Caterina Benussi; Barbara Cappagli; Massimo Ciaponi; Andrea R Genazzani
Quantitative bone ultrasonometry in climacteric women.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 1998;1(3):303-8.
1997: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; L Piaggesi; Andrea R Genazzani
Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Maturitas 1997;28(1):75-81.
1997: Domenico De Aloysio; Marco Gambacciani; P Altieri; Massimo Ciaponi; V Ventura; M Mura; Andrea R Genazzani; F Bottiglioni
Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1997;11(4):289-93.
1997: Marco Gambacciani; Massimo Ciaponi; Barbara Cappagli; L Piaggesi; L De Simone; R Orlandi; Andrea R Genazzani
Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women.
The Journal of clinical endocrinology and metabolism 1997;82(2):414-7.
1997: Marco Gambacciani; Barbara Cappagli; L Piaggesi; Massimo Ciaponi; Andrea R Genazzani
Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
Calcified tissue international 1997;61 Suppl 1():S15-8.
1995: Marco Gambacciani; A Spinetti; R Orlandi; L Piaggesi; Barbara Cappagli; C Weiss; Massimo Ciaponi; Andrea R Genazzani
Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome.
Maturitas 1995;22(2):115-20.
1995: Marco Gambacciani; A Spinetti; R Gallo; Barbara Cappagli; G C Teti; V Facchini
Ultrasonographic bone characteristics during normal pregnancy: longitudinal and cross-sectional evaluation.
American journal of obstetrics and gynecology 1995;173(3 Pt 1):890-3.
1995: Marco Gambacciani; A Spinetti; F Taponeco; Massimo Ciaponi; G P Cima; G C Teti; Andrea R Genazzani
Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1995;9(2):131-5.
1995: Marco Gambacciani; A Spinetti; F Taponeco; L Piaggesi; Barbara Cappagli; Massimo Ciaponi; L C Rovati; Andrea R Genazzani
Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1995;5(6):467-71.
1994: WG Rossmanith; Marco Gambacciani
Autonomous gonadotropin release from the human pituitary in vitro and factors influencing this secretion.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1994;8(4):265-75.
1994: Marco Gambacciani; A Spinetti; Barbara Cappagli; F Taponeco; S Maffei; L Piaggesi; Franca Fruzzetti; P Fioretti
Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism.
Maturitas 1994;19(2):125-31.
1994: Marco Gambacciani; A Spinetti; L Piaggesi; Barbara Cappagli; F Taponeco; P Manetti; C Weiss; G C Teti; P La Commare; V Facchini
Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
Bone and mineral 1994;26(1):19-26.
1994: Marco Gambacciani; A Spinetti; F Taponeco; Barbara Cappagli; L Piaggesi; P Fioretti
Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism.
Obstetrics and gynecology 1994;83(3):392-6.
1994: Marco Gambacciani; A Spinetti; F Taponeco; Barbara Cappagli; S Maffei; P Manetti; L Piaggesi; P Fioretti
Bone loss in perimenopausal women: a longitudinal study.
Maturitas 1994;18(3):191-7.
1993: Marco Gambacciani; A Spinetti; L de Simone; Barbara Cappagli; S Maffei; F Taponeco; P Fioretti
The relative contributions of menopause and aging to postmenopausal vertebral osteopenia.
The Journal of clinical endocrinology and metabolism 1993;77(5):1148-51.
1993: Marco Gambacciani; A Spinetti; Barbara Cappagli; F Taponeco; R Felipetto; Donatella Parrini; N Cappelli; P Fioretti
Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Journal of endocrinological investigation 1993;16(5):333-7.
1992: P Fioretti; Marco Gambacciani; F Taponeco; Gian Benedetto Melis; N Capelli; A Spinetti
Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women.
Maturitas 1992;15(3):225-32.
1992: Gian Benedetto Melis; Anna Maria Paoletti; Angelo Cagnacci; L Bufalino; A Spinetti; Marco Gambacciani; P Fioretti
Lack of any estrogenic effect of ipriflavone in postmenopausal women.
Journal of endocrinological investigation 1992;15(10):755-61.
1992: G B Melis; A M Paoletti; R Bartolini; M Tosti Balducci; G B Massi; V Bruni; AM Becorpi; S Ottanelli; P Fioretti; Marco Gambacciani
Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Bone and mineral 1992;19 Suppl 1():S49-56.
1991: Angelo Cagnacci; Gian Benedetto Melis; R Soldani; Anna Maria Paoletti; Marco Gambacciani; A Spinetti; P Fioretti
Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women.
Maturitas 1991;13(4):283-96.
1991: P Fioretti; Marco Gambacciani; A Spinetti; Angelo Cagnacci; Anna Maria Paoletti; R Felipetto; Gian Benedetto Melis
Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate.
Annals of the New York Academy of Sciences 1991;622():302-6.
1989: Angelo Cagnacci; Gian Benedetto Melis; Anna Maria Paoletti; Marco Gambacciani; R Soldani; A Spinetti; P Fioretti
Influence of oestradiol and progesterone on pulsatile LH secretion in postmenopausal women.
Clinical endocrinology 1989;31(5):541-50.
1989: Gian Benedetto Melis; Marco Gambacciani; Anna Maria Paoletti; Valerio Mais; D Sghedoni; P Fioretti
Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Fertility and sterility 1989;52(3):412-5.
1989: P Fioretti; Angelo Cagnacci; Anna Maria Paoletti; Marco Gambacciani; R Soldani; G A Mauro; A Spinetti; Gian Benedetto Melis
Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women.
Journal of endocrinological investigation 1989;12(5):295-301.
1989: Angelo Cagnacci; Gian Benedetto Melis; R Soldani; Marco Gambacciani; Anna Maria Paoletti; P Fioretti
Regulation of body temperature in postmenopausal women: interactions between bromocriptine and the endogenous opioid system.
Life sciences 1989;44(19):1395-402.
1988: Gian Benedetto Melis; Marco Gambacciani; Angelo Cagnacci; Anna Maria Paoletti; Valerio Mais; P Fioretti
Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women.
Obstetrics and gynecology 1988;72(5):688-92.
1988: Gian Benedetto Melis; Angelo Cagnacci; Marco Gambacciani; Anna Maria Paoletti; L Moggi; P Fioretti
Restoration of luteinizing hormone response to naloxone in postmenopausal women by chronic administration of the antidopaminergic drug veralipride.
The Journal of clinical endocrinology and metabolism 1988;66(5):964-7.
1988: Gian Benedetto Melis; Valerio Mais; Anna Maria Paoletti; F Beneventi; Marco Gambacciani; P Fioretti
Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.
Obstetrics and gynecology 1988;71(3 Pt 1):311-4.
1988: Gian Benedetto Melis; Angelo Cagnacci; Marco Gambacciani; Anna Maria Paoletti; T Caffi; P Fioretti
Chronic bromocriptine administration restores luteinizing hormone response to naloxone in postmenopausal women.
Neuroendocrinology 1988;47(2):159-63.
1987: Gian Benedetto Melis; Marco Gambacciani; Anna Maria Paoletti; F Beneventi; Valerio Mais; P Baroldi; P Fioretti
Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
The Journal of clinical endocrinology and metabolism 1987;65(3):541-5.
1987: Marco Gambacciani; Gian Benedetto Melis; Anna Maria Paoletti; Angelo Cagnacci; Valerio Mais; F D Petacchi; P Fioretti
Pulsatile luteinizing hormone release in postmenopausal women: effect of chronic bromocriptine administration.
The Journal of clinical endocrinology and metabolism 1987;65(3):465-8.
1987: Gian Benedetto Melis; Valerio Mais; Marco Gambacciani; Anna Maria Paoletti; D Antinori; P Fioretti
Dexamethasone reduces the postcastration gonadotropin rise in women.
The Journal of clinical endocrinology and metabolism 1987;65(2):237-41.
1986: Lucio Zichella; Paolo Falaschi; P Fioretti; G B Melis; Angelo Cagnacci; Marco Gambacciani; S Mancini
Effects of different dopamine agonists and antagonists on post-menopausal hot flushes.
Maturitas 1986;8(3):229-37.
1985: Gian Benedetto Melis; Marco Gambacciani; Anna Maria Paoletti; Valerio Mais; Angelo Cagnacci; F D Petacchi; P Fioretti
Sex steroids modulate prolactin response to naloxone in postmenopausal women.
Neuroendocrinology 1985;41(2):138-41.
1985: Gian Benedetto Melis; T Gargiulo; A Pallotti; Marco Gambacciani; Angelo Cagnacci; Anna Maria Paoletti; F D Petacchi; P Fioretti
Disappearance of opioid control of LH secretion in short term ovariectomized women.
Journal of endocrinological investigation 1985;8 Suppl 2():41-6.
1984: G B Melis; A M Paoletti; Marco Gambacciani; Valerio Mais; P Fioretti
Evidence that estrogens inhibit LH secretion through opioids in postmenopausal women using naloxone.
Neuroendocrinology 1984;39(1):60-3.
1982: G B Melis; A M Paoletti; Valerio Mais; N M Mastrapasqua; F A L Strigini; Franca Fruzzetti; G Guarnieri; Marco Gambacciani; P Fioretti
Dose-related effects of gamma-amino beta-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women.
Journal of endocrinological investigation 1982;5(2):101-6.
1982: G B Melis; A M Paoletti; Valerio Mais; N M Mastrapasqua; F A L Strigini; Franca Fruzzetti; G Guarnieri; Marco Gambacciani; P Fioretti
The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects.
The Journal of clinical endocrinology and metabolism 1982;54(3):485-9.
1981: G B Melis; A M Paoletti; Valerio Mais; Marco Gambacciani; G Guarnieri; F A L Strigini; Franca Fruzzetti; P Fioretti
Inhibitory effect of the dopamine agonist bromocriptine on the postcastration gonadotrophin rise in women.
The Journal of clinical endocrinology and metabolism 1981;53(3):530-5.